Skip to main content

Coloplast A/S – Announcement no. 14/2020 – Decisions of Annual General Meeting 2020

Written by Customer Service on . Posted in Public Companies.

Resolutions adopted at the Annual General Meeting 2020Today, 3 December 2020, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:The annual report for the financial year 2019/20 was adopted.Distribution of year-end dividend of DKK 13.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half-year result, this brings the total dividend paid for the year to DKK 18.00 per share of nominally DKK 1.The remuneration report for the financial year 2019/20 was approved.The remuneration of the members of the Board of Directors for the financial year 2020/21 was approved.The proposals from the Board of Directors were adopted:Updated remuneration policyAmendment of Article 2 – ObjectsAdoption of a new Article 11 – Authorisation to the Board of Directors to hold electronic general meetingsThe shareholder proposal was adopted:For the Board of Directors to complete an assessment of the viability of Coloplast to publish corporate country-by-country tax reporting in line with the Global Reporting Initiative’s standard (GRO 207: Tax 2019) starting from Financial Year 2021/22. The findings of the assessment should be made public before the AGM in 2021.Lars Søren Rasmussen, Niels Peter Louis-Hansen, Birgitte Nielsen, Carsten Hellmann and Jette Nygaard-Andersen were re-elected to the Board of Directors. Marianne Wiinholt was elected as a new member of the Board of Directors.PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected.Immediately after the Annual General Meeting, the Board of Directors elected Lars Søren Rasmussen as Chairman and Niels Peter Louis-Hansen as Deputy Chairman. In addition to the members of the Board of Directors elected at the Annual General Meeting, the Board of Directors consists of three members elected by the employees: Thomas Barfod, Nikolaj Kyhe Gundersen and Roland Vendelbo Pedersen.
For further information, please contactInvestors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 /+45 4911 3376
Email: dkebj@coloplast.comPress and media
Dennis Kaysen
Director, Corporate Communication
Tel. +45 4911 2608
Email: dkdk@coloplast.comAddress
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917Website
www.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.The Coloplast logo is a registered trademark of Coloplast A/S. © 2020-12.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.Attachment14_2020_Decisions_at_the_Annual_General_Meeting_2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.